{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:12:02Z","timestamp":1791295922693,"version":"4.1.0"},"reference-count":226,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.critrevonc.2010.01.001","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T10:36:53Z","timestamp":1267180613000},"page":"79-98","source":"Crossref","is-referenced-by-count":29,"title":["Neoplastic stem cells: Current concepts and clinical perspectives"],"prefix":"10.1016","volume":"76","author":[{"given":"Axel","family":"Schulenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Br\u00e4mswig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Karlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Mirkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hubmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Laffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Marian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Pehamberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph C.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2010.01.001_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.copbio.2007.10.007","article-title":"Cancer stem cells in solid tumors","volume":"18","author":"Ailles","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.gde.2008.01.017","article-title":"Recent advances in cancer stem cells","volume":"18","author":"Cho","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.med.58.062105.204854","article-title":"Cancer stem cells: models and concepts","volume":"58","author":"Dalerba","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00063030-200721050-00002","article-title":"Selective targeting of cancer stem cells: a new concept in cancer therapeutics","volume":"21","author":"Korkaya","year":"2007","journal-title":"BioDrugs"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/092986709787315531","article-title":"Cancer stem cells: the emerging challenge of drug targeting","volume":"16","author":"Besancon","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm1379","article-title":"Roots and stems: stem cells in cancer","volume":"12","author":"Polyak","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bmt.1701564","article-title":"Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD\/SCID mice","volume":"23","author":"Bonnet","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib10","doi-asserted-by":"crossref","unstructured":"Pearson T, Greiner DL, Shultz LD. Creation of \u201chumanized\u201d mice to study human immunity. Curr Protoc Immunol 2008 [Chapter 15:Unit 15 21].","DOI":"10.1002\/0471142735.im1521s81"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-540-75647-7_5","article-title":"The differentiative and regenerative properties of human hematopoietic stem\/progenitor cells in NOD-SCID\/IL2rgamma(null) mice","volume":"324","author":"Ishikawa","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","article-title":"Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer","volume":"1","author":"Hermann","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib13","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib16","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2008.01.013","article-title":"Significance of CD90+ cancer stem cells in human liver cancer","volume":"13","author":"Yang","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib18","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1073\/pnas.94.10.5320","article-title":"Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice","volume":"94","author":"Bhatia","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CCO.0b013e328011a8d6","article-title":"Cancer stem cells and oncology therapeutics","volume":"19","author":"Al-Hajj","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2307\/3570892","article-title":"A direct measurement of the radiation sensitivity of normal mouse bone marrow cells","volume":"14","author":"Till","year":"1961","journal-title":"Radiat Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2007-10-118331","article-title":"Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells","volume":"112","author":"Taussig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","article-title":"Efficient tumour formation by single human melanoma cells","volume":"456","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib24","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.1061803","article-title":"In vitro propagation and transcriptional profiling of human mammary stem\/progenitor cells","volume":"17","author":"Dontu","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","article-title":"Identification and expansion of human colon-cancer-initiating cells","volume":"445","author":"Ricci-Vitiani","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib27","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.2036535100","article-title":"Cancerous stem cells can arise from pediatric brain tumors","volume":"100","author":"Hemmati","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib28","doi-asserted-by":"crossref","first-page":"13427","DOI":"10.1073\/pnas.0805706105","article-title":"Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity","volume":"105","author":"Vermeulen","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jcp.1040910303","article-title":"Conditions controlling the proliferation of haemopoietic stem cells in vitro","volume":"91","author":"Dexter","year":"1977","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.leukres.2008.11.011","article-title":"In vitro biology of human myeloid leukemia","volume":"33","author":"Mayani","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI111797","article-title":"Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases","volume":"75","author":"Coulombel","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10428199909169609","article-title":"Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells","volume":"35","author":"Lagneaux","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2141.1996.00305.x","article-title":"Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro","volume":"92","author":"Panayiotidis","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/dbio.1996.0090","article-title":"Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell","volume":"175","author":"Reynolds","year":"1996","journal-title":"Dev Biol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nature04957","article-title":"The stem-cell niche as an entity of action","volume":"441","author":"Scadden","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/blood.V72.2.373.373","article-title":"Cellular interactions","volume":"72","author":"Torok-Storb","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/1040-8428(91)90018-8","article-title":"The hematopoietic microenvironment","volume":"11","author":"Greenberger","year":"1991","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0609.1992.tb00053.x","article-title":"Biology of the hemopoietic microenvironment","volume":"49","author":"Mayani","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib39","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0301-472X(98)00082-4","article-title":"Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation","volume":"27","author":"Rosel","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.exphem.2008.12.005","article-title":"Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion","volume":"37","author":"Alakel","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jcb.22258","article-title":"The cell adhesion nectin-like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells","volume":"108","author":"Raveh","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib42","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14712598.8.11.1749","article-title":"L1-CAM in cancerous tissues","volume":"8","author":"Gavert","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib43","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1158\/0008-5472.CAN-08-1079","article-title":"Targeting cancer stem cells through L1CAM suppresses glioma growth","volume":"68","author":"Bao","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice","volume":"445","author":"O\u2019Brien","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib45","doi-asserted-by":"crossref","first-page":"10158","DOI":"10.1073\/pnas.0703478104","article-title":"Phenotypic characterization of human colorectal cancer stem cells","volume":"104","author":"Dalerba","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib46","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1006\/bbrc.2001.5271","article-title":"Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein","volume":"285","author":"Corbeil","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib47","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1074\/jbc.275.8.5512","article-title":"The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions","volume":"275","author":"Corbeil","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.biocel.2004.08.010","article-title":"AC133\/CD133\/Prominin-1","volume":"37","author":"Shmelkov","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib49","first-page":"47","article-title":"CD44: a multitude of isoforms with diverse functions","volume":"184","author":"Gunthert","year":"1993","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nm1703","article-title":"Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone","volume":"14","author":"Sackstein","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib51","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjc.6604242","article-title":"CD44+ CD24(\u2212) prostate cells are early cancer progenitor\/stem cells that provide a model for patients with poor prognosis","volume":"98","author":"Hurt","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/path.2220","article-title":"CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2)","volume":"213","author":"Schulenburg","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib53","first-page":"19","article-title":"Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis","volume":"6","author":"Botchkina","year":"2009","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating human melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib55","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.03.048","article-title":"Side population cells in human cancers","volume":"268","author":"Wu","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbrc.2009.05.048","article-title":"Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer","volume":"385","author":"Chen","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1541-7786.MCR-08-0393","article-title":"Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer","volume":"7","author":"Jiang","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cbi.2008.09.029","article-title":"Aldehyde dehydrogenase activity as a functional marker for lung cancer","volume":"178","author":"Ucar","year":"2009","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib60","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1582-4934.2008.00455.x","article-title":"High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability","volume":"13","author":"Croker","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib61","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.leu.2404721","article-title":"Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD\/SCID engrafting potential","volume":"21","author":"Cheung","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib62","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1158\/1541-7786.MCR-08-0035","article-title":"Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations","volume":"6","author":"Ma","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/scd.2008.0055","article-title":"ALDH1 as a functional marker of cancer stem and progenitor cells","volume":"18","author":"Douville","year":"2009","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190500272507","article-title":"Detection of molecular targets on the surface of CD34+\/CD38\u2212 stem cells in various myeloid malignancies","volume":"47","author":"Florian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib65","first-page":"483","article-title":"Phenotypic and functional characterization of CD34+\/CD38\u2212\/CD123+ leukemic progenitor (stem) cells in AML: a flow cytometric approach","author":"Herrmann","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib66","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1349-7006.2009.01151.x","article-title":"Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression","volume":"100","author":"Morimoto","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib67","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/onc.2008.207","article-title":"HER2 regulates the mammary stem\/progenitor cell population driving tumorigenesis and invasion","volume":"27","author":"Korkaya","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib68","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/157489209787002515","article-title":"Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine","volume":"4","author":"Hewish","year":"2009","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/157488809787169048","article-title":"Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells","volume":"4","author":"Gotoh","year":"2009","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib70","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.07694","article-title":"Effects of recombinant erythropoietin on breast cancer-initiating cells","volume":"9","author":"Phillips","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: from adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib72","first-page":"S3","article-title":"CD34+ cells: biological aspects","volume":"82","author":"Benedetti","year":"1996","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib73","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2407-8-118","article-title":"CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells","volume":"8","author":"Kim","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib75","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2007.10.054","article-title":"let-7 regulates self renewal and tumorigenicity of breast cancer cells","volume":"131","author":"Yu","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib76","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib77","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/146532401317248054","article-title":"CD133 (AC133) expression on AML cells and progenitors","volume":"3","author":"Vercauteren","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbmt.2004.11.007","article-title":"Complexity of the human acute myeloid leukemia stem cell compartment: implications for therapy","volume":"11","author":"Dick","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib80","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1073\/pnas.0900089106","article-title":"Dysregulated gene expression networks in human acute myelogenous leukemia stem cells","volume":"106","author":"Majeti","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib81","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib82","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib83","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.leu.2402803","article-title":"Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195","volume":"17","author":"Feldman","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib84","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib85","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib86","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib87","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc+ AML): biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib88","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2005-06-2325","article-title":"AML engraftment in the NOD\/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML","volume":"107","author":"Pearce","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib90","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.leu.2402678","article-title":"Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors","volume":"16","author":"Dorsey","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib91","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib92","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib93","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib94","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation-2008.1.436","article-title":"Chronic myeloid leukemia stem cells","volume":"2008","author":"Jamieson","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib95","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib96","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib97","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib98","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib99","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib100","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V78.6.1413.1413","article-title":"A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients","volume":"78","author":"Chen","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib101","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib102","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2008.357","article-title":"Molecular profile of CD34+ stem\/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia","volume":"23","author":"Catani","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib103","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib104","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Lataillade","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib105","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood.V95.3.1007.003k35_1007_1013","article-title":"A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia","volume":"95","author":"Cobaleda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib106","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1126\/science.1150648","article-title":"Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia","volume":"319","author":"Hong","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib107","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2008.83","article-title":"CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL","volume":"22","author":"Kong","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib108","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2008-04-154187","article-title":"Expression of CD133 on leukemia-initiating cells in childhood ALL","volume":"113","author":"Cox","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbrc.2009.02.123","article-title":"CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells","volume":"382","author":"Nishida","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib110","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood-2006-06-030445","article-title":"Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia","volume":"109","author":"Cox","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib111","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbrc.2009.03.127","article-title":"CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells","volume":"383","author":"Yamazaki","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib112","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2008-02-138172","article-title":"NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity","volume":"113","author":"Armstrong","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib113","first-page":"1116","article-title":"Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia","volume":"90","author":"De Keersmaecker","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib114","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni1045","article-title":"Notch regulation of lymphocyte development and function","volume":"5","author":"Radtke","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc1880","article-title":"Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia","volume":"6","author":"Grabher","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib116","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib117","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1158\/0008-5472.CAN-07-1198","article-title":"A novel nonobese diabetic\/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease","volume":"67","author":"Durig","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib118","doi-asserted-by":"crossref","unstructured":"Nowakowski. ABCG2 is expressed in a small population of circulating B-cells characterized by expression of self-renewal and early B-cell development genes and resistance to therapy. Blood 2008;112(11):1\u20131444, 1082.","DOI":"10.1182\/blood.V112.11.3156.3156"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib119","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/10428190410001655157","article-title":"In multiple myeloma clonotypic CD38\u2212\/CD19+\/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes","volume":"45","author":"Rasmussen","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib121","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib122","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1073\/pnas.0610117104","article-title":"Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma","volume":"104","author":"Prince","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.mlg.0000251586.15299.35","article-title":"CD133, one of the markers of cancer stem cells in Hep-2 cell line","volume":"117","author":"Zhou","year":"2007","journal-title":"Laryngoscope"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib124","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0092-8674(02)01014-0","article-title":"The beta-catenin\/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells","volume":"111","author":"van de Wetering","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib125","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib126","first-page":"1437","article-title":"Hereditary cancer, oncogenes, and antioncogenes","volume":"45","author":"Knudson","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib127","first-page":"6","article-title":"Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers","volume":"70","author":"Sell","year":"1994","journal-title":"Lab Invest"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib128","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.2007.15.5945","article-title":"Liver cancer stem cells","volume":"26","author":"Sell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib129","first-page":"409","article-title":"Origin and fate of oval cells in dipin-induced hepatocarcinogenesis in the mouse","volume":"145","author":"Factor","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/hep.510270218","article-title":"Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat","volume":"27","author":"Petersen","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib131","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","article-title":"CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway","volume":"27","author":"Ma","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib132","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/hep.22082","article-title":"Identification of local and circulating cancer stem cells in human liver cancer","volume":"47","author":"Yang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib133","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature01972","article-title":"Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours","volume":"425","author":"Berman","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib134","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2008.16.6702","article-title":"Pancreatic cancer stem cells","volume":"26","author":"Lee","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib135","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/jnci\/djn168","article-title":"Lapatinib study supports cancer stem cell hypothesis, encourages industry research","volume":"100","author":"Schmidt","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib136","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10911-009-9115-y","article-title":"Resistance to endocrine therapy: are breast cancer stem cells the culprits?","volume":"14","author":"O\u2019Brien","year":"2009","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib137","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1349-7006.2005.00035.x","article-title":"Aberrant methylations in cancer cells: where do they come from?","volume":"96","author":"Ushijima","year":"2005","journal-title":"Cancer Sci"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib138","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0960-0760(92)90378-V","article-title":"Oestrogen receptor gene structure and function in breast cancer","volume":"41","author":"Watts","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib139","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.canlet.2008.09.034","article-title":"CXCR4 mediates the proliferation of glioblastoma progenitor cells","volume":"274","author":"Ehtesham","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccr.2008.12.016","article-title":"Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma","volume":"15","author":"Read","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib141","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1242\/dev.01384","article-title":"Role of p63 and basal cells in the prostate","volume":"131","author":"Kurita","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib142","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","article-title":"Prospective identification of tumorigenic prostate cancer stem cells","volume":"65","author":"Collins","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib143","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.2007.15.1472","article-title":"Prostate cancer stem cells: a new target for therapy","volume":"26","author":"Maitland","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib144","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12015-008-9033-1","article-title":"Exploring the origins of the normal prostate and prostate cancer stem cell","volume":"4","author":"Kasper","year":"2008","journal-title":"Stem Cell Rev"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib145","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/0008-5472.CAN-06-4608","article-title":"Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo","volume":"67","author":"Gu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib146","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10585-009-9242-2","article-title":"Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature","volume":"26","author":"Klarmann","year":"2009","journal-title":"Clin Exp Metast"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib147","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.onc.1209327","article-title":"Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells","volume":"25","author":"Patrawala","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib148","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1073\/pnas.0810956106","article-title":"The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations","volume":"106","author":"Dubrovska","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib149","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00280-007-0659-5","article-title":"Androgen receptor expression in prostate cancer stem cells: is there a conundrum?","volume":"62","author":"Sharifi","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib150","doi-asserted-by":"crossref","first-page":"10991","DOI":"10.1073\/pnas.0603678103","article-title":"A molecular correlate to the Gleason grading system for prostate adenocarcinoma","volume":"103","author":"True","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib151","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1158\/0008-5472.CAN-08-2242","article-title":"Identification of cancer stem cells in Ewing's sarcoma","volume":"69","author":"Suv\u00e0","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib152","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/stem.30","article-title":"Identification of gastric cancer stem cells using the cell surface marker CD44","volume":"27","author":"Takaishi","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib153","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1126\/science.1099513","article-title":"Gastric cancer originating from bone marrow-derived cells","volume":"306","author":"Houghton","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib154","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2005.03.032","article-title":"Identification of bronchioalveolar stem cells in normal lung and lung cancer","volume":"121","author":"Kim","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib155","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.cdd.4402283","article-title":"Identification and expansion of the tumorigenic lung cancer stem cell population","volume":"15","author":"Eramo","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib156","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ejcts.2009.03.063","article-title":"The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer","volume":"36","author":"Tirino","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib157","first-page":"8","article-title":"Prospective identification and characterization of ovarian cancer stem cells: implications for the treatment of chemotherapy resistant\/recurrent ovarian disease","author":"Santin","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib158","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/onc.2008.374","article-title":"Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells","volume":"28","author":"Baba","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib159","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1525-1438.2007.01056.x","article-title":"Expression of CD133-1 and CD133-2 in ovarian cancer","volume":"18","author":"Ferrandina","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib160","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1634\/stemcells.2008-0868","article-title":"CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature","volume":"27","author":"Kusumbe","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib161","doi-asserted-by":"crossref","first-page":"e5395","DOI":"10.1371\/journal.pone.0005395","article-title":"CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin","volume":"4","author":"Friedman","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib162","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ejca.2007.01.017","article-title":"Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential","volume":"43","author":"Monzani","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib163","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1634\/stemcells.2008-0601","article-title":"The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma","volume":"26","author":"Rappa","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib164","first-page":"467","article-title":"Isolation and identification of cancer stem-like cells from murine melanoma cell lines","volume":"4","author":"Dou","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib165","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1158\/0008-5472.CAN-08-0723","article-title":"Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines","volume":"68","author":"Jaksch","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib166","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2008.02.022","article-title":"MDR1 expression identifies human melanoma stem cells","volume":"368","author":"Keshet","year":"2008","journal-title":"Biochem Biophys Research Commun"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib167","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1038\/sj.onc.1206447","article-title":"Molecular plasticity of human melanoma cells","volume":"22","author":"Hendrix","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib168","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00008390-200010000-00003","article-title":"Erythropoietin receptor expression in human melanoma cells","volume":"10","author":"Selzer","year":"2000","journal-title":"Melanoma Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib169","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/jid.2009.162","article-title":"Role of erythropoietin receptor expression in malignant melanoma","volume":"130","author":"Mirmohammadsadegh","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib170","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0002-9440(10)62303-6","article-title":"Functional erythropoietin autocrine loop in melanoma","volume":"166","author":"Kumar","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib171","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.cmr.0000222594.60611.c3","article-title":"Erythropoietin activates the phosphoinositide 3-kinase\/Akt pathway in human melanoma cells","volume":"16","author":"Kumar","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib172","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1385\/MO:22:3:241","article-title":"The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma","volume":"22","author":"Tas","year":"2005","journal-title":"Med Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib173","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/bjc.1953.8","article-title":"A new theory on cancer-inducing mechanism","volume":"7","author":"Nordling","year":"1953","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1954.1","article-title":"The age distribution of cancer and a multi-stage theory of carcinogenesis","volume":"8","author":"Armitage","year":"1954","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib175","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib176","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/255197a0","article-title":"Mutation selection and the natural history of cancer","volume":"255","author":"Cairns","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib177","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib178","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib179","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ncponc1089","article-title":"Mechanisms of disease: epithelial-mesenchymal transition\u2014does cellular plasticity fuel neoplastic progression?","volume":"5","author":"Turley","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib180","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJMoa033153","article-title":"Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas","volume":"351","author":"Streubel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib181","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V85.12.3636.bloodjournal85123636","article-title":"Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages","volume":"85","author":"Bhatia","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib182","first-page":"3837","article-title":"Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone","volume":"27","author":"Wohrer","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib183","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.leukres.2006.04.013","article-title":"Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion","volume":"30","author":"Jootar","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib184","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib185","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/10428190801923212","article-title":"Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia","volume":"49","author":"Valent","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib186","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1056\/NEJMp048120","article-title":"Chronic myelogenous leukemia\u2014identifying the hydra's heads","volume":"351","author":"Clarke","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib187","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib188","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib189","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1182\/blood.V112.11.2956.2956","article-title":"A phase 1 and correlative biological study of CSL360(anti-CD123 mAb) in AML","volume":"112","author":"Roberts","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib191","doi-asserted-by":"crossref","first-page":"3109S","DOI":"10.1093\/jn\/131.11.3109S","article-title":"Insulin, insulin-like growth factors and colon cancer: a review of the evidence","volume":"131","author":"Giovannucci","year":"2001","journal-title":"J Nutr"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib192","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0959-437X(01)00259-3","article-title":"TGF-beta signaling: positive and negative effects on tumorigenesis","volume":"12","author":"Wakefield","year":"2002","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib193","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/156800909789057006","article-title":"The role of fibroblast growth factors in tumor growth","volume":"9","author":"Korc","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib194","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","article-title":"Survival of acute myeloid leukemia cells requires PI3 kinase activation","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib195","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/cc.4.11.2159","article-title":"mTOR, a new therapeutic target in acute myeloid leukemia","volume":"4","author":"Recher","year":"2005","journal-title":"Cell Cycle (Georgetown, Tex)"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib196","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2362.2009.02101.x","article-title":"Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells","volume":"39","author":"B\u00f6hm","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib197","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2007-09-114454","article-title":"Potentiation of antileukemic therapies by the dual PI3K\/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells","volume":"111","author":"Weisberg","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib198","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib199","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib201","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib203","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib204","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdm474","article-title":"Randomized phase II study of cetuximab plus cisplatin\/vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer","volume":"19","author":"Rosell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib205","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib206","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1078-0432.CCR-03-0043","article-title":"Determinants of rapamycin sensitivity in breast cancer cells","volume":"10","author":"Noh","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib207","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","article-title":"Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer","volume":"91","author":"Chan","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib208","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.ejca.2007.05.021","article-title":"Boezen HM, van der Graaf WT, The insulin-like growth factor 1 receptor in cancer: old focus, new future","volume":"43","author":"Hartog","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib209","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10911-008-9104-6","article-title":"IGF-1 receptor inhibitors in clinical trials\u2014early lessons","volume":"13","author":"Weroha","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12192-008-0035-3","article-title":"Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells","volume":"13","author":"Flandrin","year":"2008","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib211","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.leukres.2005.02.010","article-title":"Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia","volume":"29","author":"Thomas","year":"2005","journal-title":"Leukemia Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib212","first-page":"225","article-title":"Heat shock proteins and acute leukemias","volume":"10","author":"Thomas","year":"2005","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib213","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood-2006-11-055723","article-title":"Targeting of heat shock protein 32 (Hsp32)\/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib","volume":"111","author":"Mayerhofer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib214","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2174\/156800909789057024","article-title":"Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy","volume":"9","author":"Gleixner","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib215","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1038\/sj.onc.1207947","article-title":"Self-renewal and solid tumor stem cells","volume":"23","author":"Al-Hajj","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib216","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jcb.21436","article-title":"The stem cell hypothesis in head and neck cancer","volume":"103","author":"Graziano","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib217","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bjc.6603505","article-title":"EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges","volume":"96","author":"Chaudry","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib218","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1096\/fj.05-5460rev","article-title":"Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis","volume":"20","author":"Rege","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib219","first-page":"98","article-title":"CD123 (interleukin 3 receptor alpha chain)","volume":"15","author":"Moretti","year":"2001","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib220","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.it.2003.09.011","article-title":"Tetraspanins: molecular organisers of the leukocyte surface","volume":"24","author":"Tarrant","year":"2003","journal-title":"Trends Immunol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib221","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib222","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/0091270005276905","article-title":"Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis","volume":"45","author":"Donnenberg","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib223","doi-asserted-by":"crossref","first-page":"47156","DOI":"10.1074\/jbc.M308700200","article-title":"Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter","volume":"278","author":"Frank","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib224","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","article-title":"ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma","volume":"65","author":"Frank","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib225","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.01.001_bib226","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jama.293.1.90","article-title":"New avenues of exploration for erythropoietin","volume":"293","author":"Maiese","year":"2005","journal-title":"JAMA"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T03:58:17Z","timestamp":1635047897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842810000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":226,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S1040842810000028"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2010.01.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}